Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Critical Illness × Spironolactone × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Polycystic Ovary Syndrome 9 Neoplasms 4 Hyperandrogenism 4 Inflammation 2 Heart Failure 2 Urinary Tract Infections 1 Triple Negative Breast Neoplasms 1 Staphylococcal Infections 1 Spasm 1 Sleep Initiation and Maintenance Disorders 1 Skin Diseases 1 Sepsis 1 Seizures 1 Schizophrenia, Treatment-Resistant 1 Schizophrenia 1 Retinitis 1 Renal Insufficiency, Chronic 1 Rare Diseases 1 Pulmonary Arterial Hypertension 1 Pneumonia 1 Pain 1 Obesity 1 Neutropenia 1 Neoplasm Metastasis 1 Migraine Disorders 1 Metabolic Syndrome 1 Menorrhagia 1 Meningitis, Bacterial 1 Meningitis 1 Leukemia, Myeloid, Acute 1

Interventions

Spironolactone 1 Metoclopramide 1 Methods 1 Health Information Exchange 1 Glucose 1 Enteral Nutrition 1 Darbepoetin alfa 1 Cholecalciferol 1 Blood Specimen Collection 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02531412 2017-01-04

SPIROCAN

Instituto Nacional de Cancerologia de Mexico

Phase 2/3 Unknown

Neoplasms, Critical Illness, Acute Kidney Injury

Data powered by HemOnc (CC BY 4.0) Colophon ⚡